Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease VWD) Patients <6 Years of Age

PHASE3CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 28, 2021

Primary Completion Date

December 18, 2024

Study Completion Date

December 18, 2024

Conditions
Von Willebrand Disease
Interventions
DRUG

wilate

wilate is a plasma-derived, stable, highly purified, double virus inactivated concentrate of freeze-dried active VWF and factor VIII (FVIII) prepared from cryoprecipitate and intended for the treatment of patients with von Willebrand disease (VWD) and/or haemophilia A

Trial Locations (9)

70118

Tulane University, New Orleans

Unknown

University Hospital Ostrava Department for Pediatric Medicine, Ostrava

University Hospital Motol, Department of Paediatric Haematology and Oncology, Prague

Gerinnungszentrum Rhein-Ruhr Ambulanz und Fachlaboratorium für Gerinnungserkrankungen/Hämophilie, Duisburg

IMSP Mother and Child Institute, Chisinau

PHI University Clinic for Child Diseases, Skopje

FSBI National Research Medical Center of Pediatric Hematology, Oncology and Immunology, Moscow

Morozovskaya Children's Hospital, Moscow

"Danylo Halytsky Lviv National Medical University, Communal Institution of Lviv Regional Council Western Ukrainian Specialized Children's Medical Centre", Lviv

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Octapharma

INDUSTRY